We are currently moving from a Pandemic to an Endemic. Endemic diseases are often milder, but it’s important to note that this isn’t always the case. Flu, for instance, is estimated to cause up to 810,000 hospitalizations and 61,000 deaths annually in the US.
There are currently four endemic coronaviruses that, for most people, just cause a cold. SARS-CoV-2, the virus that causes COVID-19 is the next Endemic.
Whilst globally the short term objective has been to get vaccinated using any available vaccine regardless of its efficacy, moving forward we need to focus on innovative vaccine technologies namely mRNA vaccines that provide more than 90% efficacy to ensure a higher level of protection. This would not only reduce the incidences of contracting Covid-19 but will also ensure a higher quality of life, allowing you to live a healthy life without worrying about contracting a life threatening disease.
With mRNA vaccines we depend on the body to locally manufacture the viral protein to train our immune system which comes with the following advantages include:
Flu, is estimated to cause up to 810,000 hospitalizations and 61,000 deaths annually in the US. The Influenza Market size 2020: $4.8B is projected to reach $7.6B with 6.9% CAGR by 2027.
In addition to the current development of mRNA influenza vaccines we are currently advocating the use of cell based Flu vaccines.
Why Cell based Flu Vaccines?
Cell based flu vaccines will replace the current egg based vaccines currently used since the 1930's as they are designed to reflect specific flu strains more effectively which has shown a higher protection levels in the high risk age groups (65+) than its predecessor. In addition to faster manufacturing time when compared to the traditional vaccine manufacturing methodologies not needing millions of hens to produce.
Pneumonia
15% of all deaths of children under the age of 5 is due to Pneumonia which led to the death of more than 808,000 children under the age of 5 in 2017, accounting for 15% of all deaths of children under 5 years. People at-risk of pneumonia also include adults over the age of 65 and people with pre-existing health problems.
1st Generation: Chemotherapy attack cancer cells that grow faster than normal cells cause serious side effects such as hair loss and vomiting.
2nd Generation: Only target tumor cells and side effects such as drug resistance
With our focus on High Quality of life for our patients we are introducing new and innovative 3rd generation Immunotherapy solutions.
3rd Generation immune-therapy solutions: Activate immune cells to attack cancer cells minimizing side effects and drug resistance.
Rare diseases are a serious issue globally and orphan drugs used to treat them are not being developed by the pharmaceutical industry for economic reasons.
The process from discovery to commercialisation is lengthy (10 years), expensive and risky.
There are currently more than 4,000 life threatening rare diseases with no treatment, 400 million people world wide are currently suffering from rare diseases without serious treatments.
At Revon Bio we believe those patients have the same rights to a high quality of life as other patients.
Copyright © 2023 Revon Bio - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.